Product Name :
Phensuximide
Description:
Phensuximide is an orally active succinimide antiepileptic and anticonvulsant agent. Phensuximide inhibits cyclic AMP and cyclic GMP accumulation in depolarized brain tissue. Phensuximide can be used for the study of seizure and petit mal.
CAS:
86-34-0
Molecular Weight:
189.21
Formula:
C11H11NO2
Chemical Name:
1-methyl-3-phenylpyrrolidine-2,5-dione
Smiles :
CN1C(=O)CC(C2C=CC=CC=2)C1=O
InChiKey:
WLWFNJKHKGIJNW-UHFFFAOYSA-N
InChi :
InChI=1S/C11H11NO2/c1-12-10(13)7-9(11(12)14)8-5-3-2-4-6-8/h2-6,9H,7H2,1H3
Purity:
≥98% (or refer to the Certificate of Analysis)
Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition :
Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.
Shelf Life:
≥12 months if stored properly.
Stock Solution Storage:
0 – 4 oC for 1 month or refer to the Certificate of Analysis.
Additional information:
Phensuximide is an orally active succinimide antiepileptic and anticonvulsant agent. Phensuximide inhibits cyclic AMP and cyclic GMP accumulation in depolarized brain tissue. Phensuximide can be used for the study of seizure and petit mal.|Product information|CAS Number: 86-34-0|Molecular Weight: 189.21|Formula: C11H11NO2|Chemical Name: 1-methyl-3-phenylpyrrolidine-2,5-dione|Smiles: CN1C(=O)CC(C2C=CC=CC=2)C1=O|InChiKey: WLWFNJKHKGIJNW-UHFFFAOYSA-N|InChi: InChI=1S/C11H11NO2/c1-12-10(13)7-9(11(12)14)8-5-3-2-4-6-8/h2-6,9H,7H2,1H3|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Solubility: DMSO : 250 mg/mL (1321.28 mM; Need ultrasonic).|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.|Shelf Life: ≥12 months if stored properly.|Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.{{Octreotide} web|{Octreotide} Neuronal Signaling|{Octreotide} Purity & Documentation|{Octreotide} References|{Octreotide} custom synthesis|{Octreotide} Autophagy} |Drug Formulation: To be determined|HS Tariff Code: 382200|How to use|In Vitro:|Phensuximide produce depolarization-induced accumulation of cyclic GMP or cyclic AMP levels with ID50 values of 8.{{(-)-Epigallocatechin} medchemexpress|{(-)-Epigallocatechin} Autophagy|{(-)-Epigallocatechin} Biological Activity|{(-)-Epigallocatechin} Purity|{(-)-Epigallocatechin} manufacturer|{(-)-Epigallocatechin} Epigenetics} 00 mM or 6.PMID:32695810 20 mM in incubated slices of mouse cerebral cortex. Phensuximide (0.5-2.0 mM) has the ability to competitively inhibit mephenytoin 4-hydroxylase activity in human liver microsomes, the Ki and Km values are 559 μM and 235 μM, respectively.|In Vivo:|Phensuximide (intraperitoneal injection; 1.25 mmol/kg; single dose) induces mild changes in renal function, including: trace hematuria, increased proteinuria and decreased paminohippurate uptake in Sprague-Dawley rats. Phensuximide (intraperitoneal injection; 0.3 or 0.6 mmol/kg; 5-7 days) results in transient hematuria and proteinuria, but no change in the other renal function parameters studied. It is concluded that phensuximide produces mild, transient renal effects in Fischer 344 rats, and that the Fischer 344 rat is a suitable model for studying phensuximide-induced toxicity to the urinary tract.|Products are for research use only. Not for human use.|
